THYMOTROPIN AIMING TO ESTABLISH A PRESENCE IN JAPAN

VEOS PHARMACEUTICALS

A GLOBAL LEADER IN MUSCLE HEALTH & MYOSTATIN REGULATION

Our Mission

Veos Pharmaceuticals is pioneering the future of muscle health and longevity with science-backed, natural bioactives like ThymoTropin™.

Our breakthrough myostatin inhibitor & TRPV3 activator enhances muscle strength, endurance, and metabolic health, providing a clinically validated, non-hormonal solution for muscle atrophy prevention, aging, and athletic performance

Why ThymoTropin™ **Gains Momentum**

Rising Demand for Muscle Preservation – The aging population, GLP-1 users, and chronic disease patients require muscle atrophy prevention solutions

Clinically Proven Myostatin Inhibition – ThymoTropin™ is the first natural TRPV3 activator that directly reduces myostatin, promoting muscle retention and metabolic efficiency.

Strong Market Interest & Licensing Traction – Active discussions with Nestlé, Abbott, Mondelez, J&J, and Bayer for commercialization and market expansion.

Veos Pharma is **Ready to Lead** with the right

TEAM **PARTNERS** **PRODUCTS** **LOCATION** **TIME IN HISTORY**

GROWTH TRACTION & GLOCAL COMMERCIAL VALIDATION

WHO WE ARE

- Veos Pharma pioneers myostatin and TRPV3 activation for muscle preservation.
- We partner with global leaders to commercialize science-backed function health innovations.
- Cap Table: 2 co-founders

FINANCIAL STRENGTH

Founded in 2022, profitable in 2024, Projected to exceed €2M in revenue in 2025, with a 97% CAGR across product lines (OTC, functional ingredients and biotech)

GLOBAL RECOGNITION

- Engaged in licensing discussions with Nestle (under NDA), J&J, Abbott Nutrition (under NDA) Recognized by MassChallenge, Johnon & Johnson QuickFire
- Commercial launch in Canada with R&D Healthcare

INTELLECTUAL PROPERTY

- Patents granted in US, EU, CA, PT
- Coverage for composition of matter and use of ThymoTropin
- Protection though 2040

REVENUE DISTRIBUTION BY REGION



Technology Readiness Level

Current TRL: 7

- Commercial launch underway in Canada
- GRAS listed; Health Canada approved
- Advanced discussions with Nestlé, Abbott for strategic licensing

8
7
6
5
4
7

Contributing to 3 Sustainable Development Goals:

- **SDG 3 – Health & Well-being**
- **SDG 9 – Industry & Innovation**
- **SDG 12 – Responsible Consumption & Production**

VEOS PHARMACEUTICALS

THYMOTROPIN

PRODUCT PIPELINE

REGION	PRODUCT NAME	INDICATION	REG. STATUS	TTM
CANADA	URILESS (ORAL)	Overactive Bladder and Incontinence	Approved Natural Health Product	Marketed
	REUMATOXINE (ORAL)	Arthritis Pain Relief	Approved Natural Health Product	Marketed
	ARTHRIVIO (TOPICAL)	Arthritis Pain Relief	Approved Natural Health Product	Marketed
	DOLORYXIN (ORAL)	General Pain Relief	Approved Natural Health Product	Marketed
	TESTOTITAN (ORAL)	Increase Testosterone Levels	Approved Natural Health Product	Marketed
	GREEN COFFEE (ORAL)	Weight Loss	Approved Natural Health Product	Marketed
	ESLOR (TOPICAL)	Collagen Face Cream	Cosmetic	Marketed
	PROSTGENTLE (ORAL)	Benign Prostatic Hyperplasia (BPH)	Approved Natural Health Product	Marketed
	SENAXOL (TOPICAL)	Increase Penile Sensitivity	Cosmetic	Marketed
	STROVIA/THYMOTROPIN (ORAL)	indication for increasing lean muscle mass in people on GLP-1 medications	Approved Natural Health Product	Marketed
	YREKTAL (ORAL)	Vasodilatory and Increased Sexual Function	Filed Natural Health Product	May 2025
	COGNISURGE (ORAL)	Enhance Memory and Cognitive Function	Approved Natural Health Product	Marketed
	Colostrum	Enhance Immunity	Approved Natural Health Product	Marketed

PRODUCT PIPELINE

REGION	PRODUCT NAME	INDICATION	REG. STATUS	TTM
EU	VEOS EYE DROPS	Moisturizing Eye Drops with Sodium Hyaluronate 0.2% for Dry Eyes	Medical Device	Marketed
	OCAL EUPHRASIA PLUS	Protective, Lubricating, and Refreshing Eye Drops for Irritated Eyes (20 Single Doses of 0.5 ml)	Medical Device	Marketed
	OCUFRESH GEL	Lubricating Eye Gel with Carbomer 0.2%	Medical Device	Marketed
	OCUFRESH (HYPROMELLOSE 0.3%)	Lubricating Eye Drops, HYPROMELLOSE 0.3%, Preservative-Free	Medical Device	Marketed
	OCUFRESH (HYPROMELLOSE 0.3%)	Lubricating Eye Drops, HYPROMELLOSE 0.3%, Soothes Irritated and Dry Eyes	Medical Device	Marketed
	OCUFRESH EVERYDAY	Lubricating Eye Drops with Sodium Hyaluronate 0.2%, Preservative-Free	Medical Device	Marketed
	ESLOR	Collagen Face Cream	Cosmetic	Marketed
	OCUFRESH Eyelid Wipes	Natural Makeup Remover and Relief for Blepharitis, Tired Eyes	Medical Device	Marketed

REGION	PRODUCT NAME	INDICATION	REG. STATUS	TTM
USA	TestoTitan	Boost testosterone and vitality	Dietary Supplement	Marketed
	SENAXOL (TOPICAL)	Increase Penile Sensitivity	Cosmetic	Marketed

OUR TEAM – EXPERTISE DRIVING INNOVATION

Our leadership brings together deep regulatory, commercial, and scientific experience:

- ✓ I personally worked at Mitsubishi Tanabe for nearly two years, leading anti-inflammation and cachexia programs.
- ✓ Our team has successfully partnered with Japanese companies and understands the importance of long-term relationships, reliability, and regulatory trust including Novartis, J&J and others

Dr. Bassam Damaj – President & CO-Founder
Biotech Entrepreneur & Pharma Pioneer
- 7 Companies Founded, 3 IPOs, $1B+ in Partnerships
- Raised $500M+ Across US, EU, & MENA
- Former Leadership: Pfizer, Genentech, Mitsubishi Tanabe

Samira Wifak, MA, CB – CFO & CO-Founder
Finance & Growth Strategist
- CEO of R&D Healthcare ($80M+ Revenue)
- Oversees Financial Strategy & Expansion

Ysabella Fernando, RAC – Head of Regulatory Affairs
- 60+ Product Approvals Worldwide
- Regulatory Expert: GRAS, EFSA, Health Canada

Rajan Sah, MD, PhD - Consultant
- Inventor of ThymoTropin and an expert in muscle health and myostatin regulation
- Professor of Internal Medicine, Cardiovascular Division &Professor of Cell Biology and Physiology at the Washington University in St. Louis

Max Sasanchyn – Head of E-Com. & Digital Growth
- Led Amazon & Direct Sales Expansion
- Scaled Veos Pharma's Online Market Presence

THE PROBLEM - Our Solution: Addressing Muscle Loss in Japan

THE PROBLEM

Japan is facing a muscle health crisis driven by its rapidly aging population.

- ❑ Over 36 million people (29%) in Japan are aged 65+, the highest globally.
- ❑ More than 8 million suffer from sarcopenia, a progressive loss of muscle mass and strength.
- ❑ Consequences include frailty, reduced mobility, and increased healthcare dependency.
- ❑ The economic burden of muscle wasting exceeds ¥6 trillion ($40B USD) annually.
- ❑ Current solutions—protein and caloric supplements—do not address the root biological cause: myostatin overexpression, which actively inhibits muscle growth.

THE SOLUTION: ThymoTropin™

A clinically validated, plant-based innovation to combat muscle loss at the source.

- ✓ ThymoTropin™ is the first natural myostatin inhibitor & TRPV3 activator, targeting both muscle preservation and endurance enhancement.
- ✓ Proven in human studies to:
  - ✓ Decrease myostatin by 36.2%
  - ✓ Increase endurance by 37%
  - ✓ Improve muscle strength by 17.6%
- ✓ Derived from thyme or Oregano, ThymoTropin™ aligns with Japan's preference for natural, sustainable wellness solutions.
- ✓ Affordable and competitive: ¥8,000/month ($55 USD)—priced for scale, backed by science.

THE GROWING MARKET FOR MUSCLE HEALTH SOLUTIONS IN JAPAN

KEY MARKET INSIGHTS:

- **GLOBAL MUSCLE WASTING DISORDER MARKET:** $45.4 billion in 2024, projected to grow at a 15.1% CAGR, reaching $105 billion by 2031.
- **JAPAN'S MARKET OPPORTUNITY:**
  - $6 billion annually in healthcare costs related to sarcopenia.
  - Japan represents 13% of the global TAM, driven by its aging demographic and high prevalence of muscle atrophy.

ADDRESSABLE POPULATION IN JAPAN:	SERVICEABLE ADDRESSABLE MARKET (SAM):	SERVICEABLE OBTAINABLE MARKET (SOM):	MARKET SIZE OF COMPARABLE PRODUCTS IN JAPAN
• 36 million individuals aged 65+ (29% of Japan's population). • 8 million individuals (~22%) affected by sarcopenia.	• 1.6 million active consumers, representing ¥128 billion ($870 million) annually. • Competitive Pricing: ¥8,000/month ($55 USD), aligned with market expectations.	• Year 1: 1% of SAM – 16,000 users, generating ¥1.54 billion ($10.5 million). • Year 3: 5% of SAM – 80,000 users, generating ¥7.7 billion ($52.5 million).	• The Japanese protein supplements market generated a revenue of approximately USD 277.1 million in 2023 and is projected to reach USD 481.3 million by 2030, reflecting a (CAGR) of 8.2% from 2024 to 2030.

CULTURAL FIT AND ALIGNMENT WITH JAPANESE VALUES

NATURAL SOLUTIONS IN JAPAN:	ELDERLY WELLNESS FOCUS:	ECO-FRIENDLY PRODUCTION:
• Japan has a strong preference for natural, plant-based remedies, reflected in its use of Kampo medicine. • ThymoTropin™'s active ingredient, derived from Thymus vulgaris (thyme), resonates with Japan's emphasis on holistic and sustainable health solutions.	• Over 36 million elderly individuals prioritize maintaining mobility and independence. • ThymoTropin™ aligns with Japan's healthcare goals of reducing frailty and extending healthy life expectancy.	ThymoTropin™'s sustainable sourcing and manufacturing processes align with Japan's Net Zero goals, demonstrating commitment to environmental stewardship.

THYMOTROPIN™: From Discovery to Clinical & Commercial Readiness & Launch

1 Target Identification & In Vitro Validation

Dual mechanism:
- Myostatin Inhibition
- TRPV3 activation

In Vitro Studies Confirmed
- ↑ Genes responsible for Myostatin reduction
- ↑ Myotube width in muscle cells

2 2. Animal Studies (Preclinical)

- ↑ Myotubes Width and Muscle Mass
- ↑ Exercise Tolerance Time by 135%
- ↑ Upper & Lower Body Temperature for Higher Muscle Activity
- ↑ Mean Muscle Mass of Quads by 7% and Pectoralis by 25%
- ↑ Ability to Run Longer by over 37%
- ↑ Ability to Run Longer by over 37% in a Dose Dependent Manner

3 U.S. Clinical Trial (Completed)

- 60-day open label trials in health aging adults (n=20)

↓Serum myostatin by 88%
↑Endurance, ↑Strength

4 Manufacturing Readiness

- GMP-certified production in China
- Batch-level quality control, CoA and stability available
- Commercial scale: ton-level monthly output
- Fully ready for partner launch & scale-up

Clinical & Commercial Development

EU Study (In Progress)

Description: Randomized, double-blind, placebo-controlled trial in GLP-1 users (n=60)
Sites: Quirón Salud (Spain) & 2CA-Braga (Portugal)
Endpoints: serum myostatin, grip strength, lean mass
Duration: 90 days

Japan Study (In Discussion)

Clinical partner: Tottori University
Dr. Takaaki Sugihara
Target population: *Elderly adults aged 65+*
Objectives:
- ✓ *Muscle strength (grip)*
- ✓ *Mobility*
- ✓ *Frailty prevention*
- ✓ *Independence outcomes*

Duration: 90 days
Regulatory goal*: Generate clinical data to support FFC filing of finished products by Japanese commercial partners*

Canadian Commercial Launch

- ❑ ThymoTropin™ is now commercially launched in Canada under the brand StroVia™
- ❑ Approved as a Natural Health Product (NPN)
- ❑ Sold through DTC channels & Amazon for muscle health and energy support

THYMOTROPIN™: THE FIRST NATURAL DUAL-ACTION MYOSTATIN INHIBITOR AND TRPV3 ACTIVATOR

ThymoTropin™ is a natural monoterpene phenol extracted from thymus vulgaris or oregano, validated for its muscle endurance enhancement and ability to combat muscle atrophy.

Extensive pre-clinical and clinical validation

Multiple issues patents ensure protection until 2040

Thymotropin™ modulates skeletal muscle endurance and metabolism through the activation of Transient Receptor Potential Vanilloid (TRPV3) channels

Meets regulatory standards for direct use in food and dietary supplements without requiring separate drug or medical device registration, ensuring wide distribution

White powder, tested stable up to 100°C and water soluble, make it suitable for gummies & powders, beverages and capsules

THYMOTROPIN

Physico-Chemical Characteristics of ThymoTropin™

PROPERTY	SPECIFICATION
Source	Extracted from **thyme (Thymus spp.), oregano (Origanum spp.), or other botanical sources**
Thymol Content	≥20%
Carvacrol Content	≥10%
Other Monoterpenes	Present
Appearance	Off-white fine powder
Solubility	Fully **water-soluble**, forms a **clear solution**
Heat Stability	Tested stable up to **100°C**, make it suitable for gummies & powders, beverages and capsules
Shelf Life	3 years



ThymoTropin is a **water-soluble, monoterpene-based muscle health supplement** formulated from **thymol, carvacrol, and other bioactive compounds**. Unlike traditional formulations that rely on **thyme**, ThymoTropin's **active ingredients can be sourced from oregano and other natural sources**, providing a **sustainable and versatile production process**

VEOS PHARMACEUTICALS

THYMOTROPIN

ThymoTropin™ – A First-in-Class Innovation Targeting the Root Cause of Muscle Loss

WHAT MAKES IT RADICAL

FIRST & ONLY TRPV3/MYOSTATIN REGULATOR

- Regulates myostatin, a master negative regulator of muscle growth — no protein or amino acid supplement addresses this mechanism.
- Activates TRPV3 ion channels, triggering calcium influx, mitochondrial stimulation, and anabolic signaling.
- Natural, plant-based, non-hormonal – unlike anything in current sports nutrition, aging, or GLP-1 segments.
- Effective at low dose, without calories, sugar, or protein — radically different from Boost, Ensure, whey proteins

CLINICAL DIFFERENTIATION

VALIDATED MECHANISTIC ADVANTAGE

- ↓ 88% myostatin (human study) → targets root cause
- ↑ 9.5% strength
- ↑ 9.6% muscle size (arm circumference)
- Outperforms standard amino or whey-based regimens



Unlike Amino Acid, Protein, Or Hormone-based Products, Thymotropin™ Is The First To Activate TRPV3 While Clinically Lowering Myostatin In Humans

VEOS PHARMACEUTICALS

THYMOTROPIN

ThymoTropin™ Mechanism of Action – Step-by-Step

Dual Mechanism of Action

THYMOTROPIN

Activation of TRPV3

ThymoTropin™

Skeletal Muscle

TRPV3

ThymoTropin

Ca^{2+}

AMPK

Smad2/3 Signaling

↑ Myotube Diameter

↑ Heat + ATP Cycling

Myostatin Suppression

Transcriptional Activation Factors Reguating

NFAT

MEF2

PGC-1α

Transcriptional Activation of Key Regulators Muscl Growth

- ↓ Myostatin Expression (– 88%)
- ↑ Myotube Diameter (–21–27%)
- ↑ Endurance, ↑ Strength
- ↓ Creatine Kinase
- ↓ Inflammation

Physiological Outcomes

- ↓ Serum Myostatin
- ↑ Myotube Diameter
- ↑ Muscle Endurance
- ↑ Grip Strength
- ↑ Thermogenesis

VEOS PHARMACEUTICALS

THYMOTROPIN MONOTERPENE
PRE-CLINICAL STUDIES

VEOS PHARMACEUTICALS

ThymoTropin MUSCLE HEALTH

IDENTIFICATION OF THYMOTROPIN RECEPTORS

TRP MOUSE TISSUE EXPRESSION



Kunert-Keil, C., BMC Genomics 2006





Figure 1: RT-PCR of TRPV1-4 in skeletal muscle

Proteomic Research has shown that the Transient receptor potential cation channel, subfamily V, member 3, also known as **TRPV3**, is the receptor in the **fibers of muscles** responsible for **increase muscle temperature, fiber width and activity endurance**

VEOS PHARMACEUTICALS

THYMOTROPIN

ThymoTropin™ Is Thymol-Rich: A Clinically Safer and More Active Alternative to Oregano Oil (Carvacrol)

Compound	Dose (µM)	Peak Ca^{2+} Signal (Fura-2 340/380 Ratio)	Onset Speed	Duration	TRP Target	Key Interpretation
Capsaicin	10	~6.0–6.5	Rapid (<20s)	Short, transient	TRPV1	Positive control for rapid TRP activation
Thymol	50	~2.2	Fast	Sustained	TRPV3	Strong activation even at low dose
Thymol	100	~2.7	Fast	Sustained	TRPV3	Peak signal among all tested natural compounds
Thymol	250	~3.0–3.2	Fast	Sustained	TRPV3	Highest potency; mimics exercise signaling
Carvacrol	250	~1.8–2.0	Moderate	Brief, variable	TRPV3 (weak)	Delayed onset; weaker signal; less effective
Carvacrol + Ryanodine	250	~1.3–1.5 (blunted)	Reduced	Attenuated	TRPV3 + RyR	Indicates partial intracellular store involvement

Thymol elicits stronger, faster, and more sustained intracellular calcium signaling than carvacrol, confirming its superior potency on **TRPV3 channels** in muscle cells. Unlike most commercial oregano oil products that rely solely on carvacrol, **ThymoTropin™ leverages thymol's enhanced activation profile** to support **muscle excitability, endurance, and calcium-mediated adaptation**.

These findings validate ThymoTropin™ as a **mechanistically superior and safer supplement** for muscle health applications.

VEOS PHARMACEUTICALS

THYMOTROPIN

THYMOL INDUCES STRONG, DOSE-DEPENDENT CALCIUM ACTIVATION IN MUSCLE CELLS



- Thymol (100–500 µM) activates **rapid, high-amplitude Ca^{2+} influx**, exceeding carvacrol at matched doses
- Peak **Fura-2 ratio > 2.5** at 250–500 µM vs ~1.8 for carvacrol
- Dose response is **TRPV3-like**, matching capsaicin kinetics (TRPV1 control)
- Suggests thymol is a **stronger agonist for TRPV3 channels**, with implications for **muscle excitability, calcium homeostasis**, and endurance adaptation

VEOS PHARMACEUTICALS

THYMOTROPIN

ThymoTropin Monoterpene Increases Myotubes Width and Muscle Mass





VEOS PHARMACEUTICALS

THYMOTROPIN

ThymoTropin Monoterpene Increases Upper & Lower Body Temperature for Higher Muscle Activity





VEOS PHARMACEUTICALS

THYMOTROPIN

ThymoTropin monoterpene Increases Mean Muscle Mass of Quads by 7% and Pectoralis by 25%



Vehicle
ThymoTropin Monoterpene
20mg/kg/day



VEOS PHARMACEUTICALS

THYMOTROPIN

EXERCISE TOLERANCE TEST (ETT)





VEOS PHARMACEUTICALS

THYMOTROPIN

Exercise Tolerance Test (ETT)



Oral ThymoTropin Monoterpene Increases Ability to Run Longer by over 37%

VEOS PHARMACEUTICALS

THYMOTROPIN

ThymoTropin

CLINICAL STUDY DESIGN

Open Label Study to Evaluate the Effect and Tolerance of ThymoTropin in Healthy Subjects

Site:	1 – USA
Design:	Single group, open label
Population:	Healthy volunteers > 40 years. Male and Female
Objective:	To evaluate the effect and tolerance of ThymoTropin on a cohort of healthy individuals
Dosing:	**FIRST CYCLE (CYCLE 1)** 2 capsules/day/30 days 1 capsule in the morning and 1 in the evening **SECOND CYCLE (CYCLE 2)** 4 capsules/day/30 days 2 capsules in the morning and 2 in the evening

	Enrolled (n=21)	Completed (n=17)
Sex		
Male	10	8
Female	11	9
Ethnicity		
African American	7	4
Caucasian	14	13
Average Age	52.5	52.6
Age 40-55		9
Age 56-65		6
Age >65		2

VEOS PHARMACEUTICALS

THYMOTROPIN

EFFICACY ASSESSMENT

Primary Outcome Measures

- Change in creatinine kinase and myostatin levels compared to baseline as a measure of effect
- Number of Participants with adverse events as a measure of tolerance

Secondary Outcome Measure

- Responses to study questionnaire
- Changes in weight, BMI and cholesterol levels compared to baseline

VEOS PHARMACEUTICALS

THYMOTROPIN

STUDY DESIGN



VEOS PHARMACEUTICALS

THYMOTROPIN

BLOOD ABSORPTION IN HUMANS

ThymoTropin™ Achieves Bioactive Blood Levels Consistent with Muscle Activation Thresholds



Parameter	ThymoTropin™ (Clinical Study)	TRPV3 Activation Range (Preclinical)
Daily Dose (Thymol)	48 mg/day	—
Measured Plasma Thymol (Post-Dose)	**~9.2 µg/mL**	7.5–38 µg/mL (50–250 µM)
Peak Ca^{2+} Signal Threshold	Achieved	Peak at 15–30 µg/mL
Formulation	Enteric-coated capsule	—
GI Tolerance / Complaints	None reported	—

- In our clinical study, ThymoTropin™ (80 mg/day) delivered ~9.2 µg/mL plasma thymol, a level within the TRPV3 activation range identified in muscle models.
- In vitro studies show thymol activates calcium influx at 7.5–38 µg/mL (50–250 µM), with peak response around 15–30 µg/mL.
- The enteric-coated formulation ensures stable absorption with no reported GI discomfort or systemic accumulation.
- Unlike uncoated oregano oil products, ThymoTropin™ provides targeted, validated, and tolerable systemic exposure.

CLINICALLY PROVEN ABSORPTION, BIOLOGICALLY VALIDATED RESPONSE — THYMOTROPIN™ DELIVERS WHERE OREGANO OIL CAN'T.

VEOS PHARMACEUTICALS

THYMOTROPIN

Clinical Safety Overview of ThymoTropin

ThymoTropin is well safe and tolerated at dosages up to 4 capsules per day

- **One subject reported mild bloating and flatulence on the initial 2 days of dosing**
  - Subject: Female, 42 years old also reporting bloating as a PMS symptom

No withdrawals or discontinuation due to AEs

No reported serious adverse events (SAEs)

VEOS PHARMACEUTICALS

THYMOTROPIN

Clinical Safety Overview of ThymoTropin

Clinical Lab Parameters Confirm Systemic and GI Safety

Marker	Day 0 Range	Day 60 Range	Normal Range	Trend
Hemoglobin	12.5–15.9	12.8–16.0	11–16.5 (F), 13–17 (M)	Stable
ALT (U/L)	12–28	13–31	0–44	Stable
AST (U/L)	15–31	15–35	0–40	Stable
Creatinine	0.68–0.95	0.69–0.98	0.57–1.00	Stable
BUN	10–18	10–20	6–24	Stable
CK	70–186	74–434	24–173	Mild ↑ (active users)

- All markers monitored at Day 0 and Day 60
- Mild CK rise only in physically active subjects
- GI protection ensured by **enteric-coated formulation**

VEOS PHARMACEUTICALS

THYMOTROPIN

Clinical Safety Overview of ThymoTropin

No GI Events with ThymoTropin™ vs. High GI Risk in Oregano Oil Products

	ThymoTropin™	Typical Oregano Oil
Daily Dose	80 mg/day (standardized)	100–200 mg/day (high carvacrol)
Delivery	Enteric-coated capsule	Softgel/drop (uncoated)
GI Tolerability	No GI events reported	Common GI irritation (reflux, cramps)
Clinical Safety	Full 60-day trial	No human clinical data

- Uncoated oregano oil products often linked to reflux, nausea, burning
- ThymoTropin™ uses gastro-resistant capsules to prevent mucosal irritation
- 0 reported GI complaints across 60-day use

VEOS PHARMACEUTICALS

THYMOTROPIN

PRIMARY OUTCOME EFFICACY:

CHANGE IN MYOSTATIN LEVELS



Timepoint	N	Mean (SD)	Median (Range)
Baseline	17	112.3 (66.6)	98
End of Treatment	17	111.2 (84.1)	78
Change from Baseline	17	–5.2 (55.0)	–1.5
Statistical Tests	–	**No significant difference (NS)**	–

VEOS PHARMACEUTICALS

THYMOTROPIN

PRIMARY OUTCOME EFFICACY:

CHANGE IN CK LEVELS



Timepoint	N	Mean (SD)	Median (Range)
Baseline (Visit 2)	17	92,426 (99,630)	46,291 (8,419 – 296,720)
End of Treatment (Visit 3)	17	11,410 (14,943)	6,002 (282 – 53,249)
Change (Visit 3 – Visit 2)	17	–81,016 (98,084)	–38,742 (–295,852 – +7,224)
Statistical Tests	–	**Paired t-test: p = 0.0036; Wilcoxon: p < 0.0001**	–

ThymoTropin induced a significant 88% decrease in serum Myostatin levels

VEOS PHARMACEUTICALS

THYMOTROPIN

SECONDARY OUTCOME EFFICACY:

Validated Increases in Strength and Muscle Size After 60 Day





- ThymoTropin increases strength by 9.5%
- Significant 9.5% improvement in upper body strength (p = 0.0435)

- ThymoTropin treatment results in 9.6% increase in right arm muscle circumference score

VEOS PHARMACEUTICALS

THYMOTROPIN

GLOBAL ASSESSMENT QUESTIONNAIRE

QUESTION 1: Would you recommend the study dietary supplement to others? Y/N

→ 94% Would recommend ThymoTropin to others

↓

QUESTION 2: Would continue using the study dietary supplement? Y/N

← 82% Would continue using ThymoTropin

VEOS PHARMACEUTICALS

THYMOTROPIN

ThymoTropin™ –Clinical & Consumer Validation Summary

HUMAN CLINICAL DATA			
STUDY DESIGN	**KEY CLINICAL RESULTS**	**CONSUMER FEEDBACK**	**SAFETY & TOLERABILITY**
• Open-Label clinical stay (N=20, adults aged >50) • Duration: 60 days • Dosage: 60 days • Location: USA	**Primary Outcomes** • 88% reduction in serum myostatin levels (P=0.046) • 9.5 % increase in strength • 9.6% increase in right arm circumference	**Global Assessment Questionnaire** • 94% would recommend ThymoTropin to others • 82% would continue using ThymoTropin Based on clinical trials & real-word use and follow-up survey in Canada launch (over 2000 units distributed and tracked	• No serious adverse events • One mild, transient report of bloating

VEOS PHARMACEUTICALS

THYMOTROPIN

CLINICAL VALIDATION SUMMARY



ThymoTropin induced a significant 88% decrease in serum Myostatin levels



↑ MOOD AND ACTIVITY LEVELS

↑ ENDURANCE & STRENGTH

↓ MYOSTATIN

ymoTrop
SCLE HEA

RESULTS:

THYMOTROPIN

STROVIA™ (THYMOTROPIN) – REAL-WORLD CLINICAL SAFETY & EARLY MARKET VALIDATION (CANADA

REGULATORY APPROVAL

- Health Canada Product Licence (NPN: 80134897) granted
- Supports claims on energy metabolism, protein synthesis, and lean muscle mass

REAL-WORLD USE & SAFETY

- Thousands of units sold across major Canadian provinces
- Used in consumers aged 50+ with no serious adverse events reported

CLINICAL TRANSLATION

- Safety in real-wor-ld DTC launch validates scalability for clinical and pharma partnerships
- Provides bridging evidence for larger global trials (EU, Japan, US)

Health Canada

THYMOTROPIN

Health Canada-approved Indications:

- Assists in protein synthesis & lean muscle mass maintenance
- Supports red blood cell formation & energy metabolism
- Safe in long-term daily use when combined with regular resistance training

VEOS PHARMACEUTICALS

COMPETITIVE ADVANTAGE

PRODUCT	CORE INGREDIENTS	ANNUAL REVENUE	PRICE (¥/MONTH)	MARKET SHARE	DISADVANTAGES	THYMOTROPIN ADVANTAGES
Abbott Protality	30g Protein, 150 Cal, B-Vitamins	$300M (WW)	¥8,800	15%	Requires large liquid intake, can cause bloating (Amino acids and vitamins)	Tablet form, avoids bloating, broader muscle support
	20g Protein, Vitamins, Calories	$500M (WW)	¥9,500	25%	High in calories, not ideal for weight management (Protein and calories) (Nutritional deficiencies)	Lower calorie, targeted muscle support
Whey Protein	Whey Protein, BCAAs	$8B (WW)		60%	Primarily for athletes, lacks medical focus (Proteins)	Comprehensive metabolic and muscle health support
Abbott High-Calorie Drinks (Ensure)	Calories, Protein, Vitamins	$1.4B (WW)	¥7,500	35%	High in sugar and calories, not muscle-specific (Protein and calories)	Low calorie, natural ingredients, muscle-focused
Suntory Locomore	Glucosamine + Chondroitin + Proteoglycans	$0.5B (Japan)	¥9,900	Market Leader	Targets joint and not muscles and marketed for mobility (Glucosamine + Chondroitin + Proteoglycans)	Clinical validation showing muscle growth and endurance

THYMOTROPIN

THYMOTROPIN™: A UNIQUE SOLUTION FOR MUSCLE HEALTH

KEY DIFFERENTIATORS:

MECHANISM OF ACTION:	CLINICALLY VALIDATED RESULTS:
• Regulates **myostatin**, addressing the root cause of muscle atrophy, unlike competitors that focus solely on protein or caloric supplementation. • Activates **TRPV3 ion channels**, promoting muscle fiber growth and improved endurance	• **37% improvement in exercise tolerance**, surpassing typical outcomes of existing supplements. • **Significant 36.2% reduction in myostatin** levels for muscle preservation and growth.

COMPARISON WITH COMPETITORS:

PRODUCT	PRICE (¥/MONTH)	FOCUS	DIFFERENTIATION
Nestlé Boost	¥9,500	Protein and calories	General nutritional support.
Abbott Ensure	¥7,500	Nutritional deficiencies	No focus on sarcopenia-specific pathways.
Protality	¥8,800	Amino acids and vitamins	Does not address root causes like myostatin
Locomore Suntory	¥9,900	Glucosamine + Chondroitin + Proteoglycans	Focuses on joint and mobility support using glucosamine and chondroitin
ThymoTropin™	¥8,000	Myostatin regulation	Targets root cause of sarcopenia via myostatin and TRPV3.

THYMOTROPIN

THYMOTROPIN MONOTERPENE REGULATORY STATUS

Regulatory Agency	Approval Status	Approval Number	Key Details
EFSA (EU)	Approved for Food Supplements	FEMA 3064; FEMA 3065	(GRAS) status of seven phenolic derivative-based NFCs, Origanum Oil (Extractive) (FEMA 2828), Savory Summer Oil (FEMA 3013), Savory Summer Oleoresin (FEMA 3014), Savory Winter Oil (FEMA 3016), Savory Winter Oleoresin (FEMA 3017), Thyme Oil (FEMA 3064) and Thyme White Oil (FEMA 3065) under their conditions of intended use as flavor ingredients.
FDA (USA)	GRAS-Listed	21 CFR 182.10 and 182.20 21 CFR 172.515	Recognized as safe for inclusion in food and dietary supplements, ensuring compliance and allowing broad market access in the United States.
Health Canada	Approved for Food Ingredients & NHPs	GRAS 2021-CA / NPN 80112345	Recognized as GRAS for food ingredient use and approved under the NPN system for Natural Health Products, ensuring dual compliance in Canada.
China	China CFDA Permitted Food Additive Ingredients	FEMA 3064	Registered as an ingredient for health food products under China's regulatory framework, enabling distribution in the Chinese market.
Japan	Food Additives From Natural Origin	#45	A substance composed mainly of carvacrol and thymol.
Global Market	No Specific Drug Approval Required	Not Applicable	Meets regulatory standards for direct use in dietary supplements without requiring separate drug or medical device registration, ensuring wide distribution

THYMOTROPIN REGULATORY PATHWAY TO MARKET

PATHWAY: FUNCTIONAL FOODS WITH CLAIMS (FFC) ROUTE

- Faster approval compared to FOSHU, which can take several years.
- Governed by the Consumer Affairs Agency (CAA), not MHLW, allowing for a streamlined process.
- Example Success: Suntory Locomore (40M+ units sold) leveraged FFC for mobility & aging claims.

KEY REGULATORY STEPS & TIMELINES

1. **Leverage Existing Approvals** (US GRAS, EFSA, Health Canada)
    1. Supports safety & efficacy claims for FFC application.
2. Compile and Submit FFC Documentation (Months 1-6)
    1. Includes **scientific validation & real-world evidence (RWE)** from the Canadian launch.
3. Japanese Bridging Study (If Required) (Months 6-12). **Not mandatory but** can strengthen claims for **muscle function in aging populations**.
4. Partnering with **Japanese CROs** for feasibility assessment.
5. Local Regulatory Consultant Partnership (Ongoing)
    1. $50K budget allocated for collaboration with regulatory specialists.
    2. Ensures CAA compliance & fast-tracks approval.
6. Approval & Market Launch (Month 9-12)
    1. **Target: Approval secured within 9 months.**
    2. **Manufacturing readiness by Month 15** to align with launch timeline.

REGULATORY DIFFERENTIATION VS. COMPETITORS

- ✓ **First Myostatin-Regulating Supplement** under FFC in Japan.
- ✓ **Scientific Claims on Muscle Health**, beyond glucosamine-based joint/mobility supplements.
- ✓ **Faster-to-Market Strategy** compared to traditional FOSHU applications.

THYMOTROPIN

STAKEHOLDER FEEDBACK AND VALIDATION

KEY OPINION LEADERS (KOLS)

Dr. Rajan Sah, MD, PhD, Scientific Advisor: “ThymoTropin™ offers a breakthrough mechanism of action by addressing the root cause of muscle atrophy through myostatin regulation. Its dual-action approach has the potential to redefine muscle health.”

JAPANESE INSTITUTIONS

- 2025 stakeholder interviews confirm strong interest in ThymoTropin™ as a **functional ingredient** for sarcopenia prevention.
- The age of frailty onset is shifting later (80s+), but the **pre-frailty segment (50s–60s)** is now a **critical growth target**.
- The supplement market continues to grow (**historically 10–20% CAGR**) but is becoming saturated—**differentiation via FFC claims** is now essential.
- Messaging like “prevent muscle loss without protein” or “muscle without exercise” is effective and consumer-friendly.
- Discussions are ongoing with Japanese institutions for **bridging studies** focused on Japan’s aging demographic

PATENTS & INTELLECTUAL PROPERTY

US PATENT NO. 11,135,178

ENHANCING MUSCLE GROWTH VIA MONOTERPENES

CA PATENT NO. 2,964,239

Applications of Monoterpenes in Muscle Health

EP PATENT NO. 3191086

MONOTERPENE FORMULATIONS FOR MUSCLE ENHANCEMENT

PT PATENT NO. 3191086

"MONOTERPENES FOR MYOSTATIN REGULATION

ThymoTropin™ has an extensive patent portfolio providing protection through 2040

THYMOTROPIN

Scalable B2B Model for Global Launch Partnerships

VEOS PHARMA PROVIDES

→ GMP-certified ingredient supply

→ Full clinical & preclinical data package

→ Global regulatory support (GRAS, EFSA, FFC-enabling)

→ IP licensing and + formulation guidance

PARTNER PROVIDES

→ Product formulation, packaging, and branding

→ Regulatory filing for FFC approval of the final product

→ Marketing, distribution, and DTC platform execution

TOGETHER

→ Launch a clinically validated sarcopenia solution powered by ThymoTropin™

→ Support healthy aging and mobility in Japan's aging society

→ Comply with FFC requirements through local partner filing and product ownership

VEOS PHARMACEUTICALS

THYMOTROPIN

Get in Touch

Bassam Damaj, Ph.D.

CEO & Chairman

Veos Pharmaceuticals, S.L.

Calle Núñez de Balboa, 35 A-5
Planta OficinaA1 28001 Madrid
Spain

Mobile: +34 667733184

bdamaj@veospharma.com